Peps
There is no single answer for “peptides”
Peptides range from approved drugs with years of safety monitoring to research compounds never tested in people, so the cancer question has to be asked one compound at a time. The evidence also comes in very different strengths: drug labels, animal studies, lab experiments and single case reports.
Approved peptide drugs with cancer warnings on their labels
Semaglutide, tirzepatide, liraglutide and dulaglutide caused thyroid C-cell tumors in rodents. Their labels say it is unknown whether they do so in people, and tell anyone with a personal or family history of medullary thyroid cancer, or the MEN 2 syndrome, not to use them. Teriparatide and abaloparatide caused bone cancer (osteosarcoma) in rats, and their labels advise avoiding them in people at higher risk of it. Tesamorelin’s label warns of possible growth or return of cancers.
These warnings come from the long-term animal studies and trials required for approval, and the labels say who should avoid each drug. They do not show that the drugs cause cancer in people generally.
Source: dailymed.nlm.nih.gov ↗
Source: dailymed.nlm.nih.gov ↗
Source: dailymed.nlm.nih.gov ↗
Research peptides: unknown risk, with a few lab signals
For most research peptides there are no long-term human studies at all, so their cancer risk is simply unknown. A few have specific concerns from laboratory and animal work: higher levels of thymosin beta-4, the parent protein of TB-500, have been linked to tumor spread and blood-vessel growth in tumor studies, and the FDA has noted animal findings suggesting LL-37 could promote tumors in some tissues.
Growth-hormone secretagogues such as ipamorelin, CJC-1295 and MK-677 raise growth hormone and IGF-1, signals that help cells grow; in trials, MK-677 raised IGF-1 in older adults. Whether raising them this way changes cancer risk in people has not been studied.
Source: fda.gov ↗
Case reports: why one patient isn’t proof
Melanotan II, an unapproved tanning peptide, has case reports of new or changing moles and of melanoma during or soon after use. In a case covered in October 2026, the man also used tanning beds and anabolic steroids and had a personal and family history of melanoma, and his doctors said the cancer could not be blamed on the injections alone.
Case reports are useful warnings, but they cannot show cause: there is no comparison group, and people who use tanning injections often also get more sun. Reviews of these unregulated tanning products urge caution for that reason.
Source: Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. ↗
Source: skincancer.org ↗
What to take away
Approved peptide drugs carry known, labeled cancer warnings for specific groups of people. Research peptides mostly have unknown long-term risk, with a few laboratory signals worth taking seriously. Neither a frightening headline nor an absence of studies settles the question. Each PepsRadar profile’s Risks & interactions section lists what is known, and the cancer page under Health conditions shows which profiles flag it. PepsRadar gives no dosing or usage information.
Continue with the original research
Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.